Group 1: Revenue Growth Drivers - The key revenue growth drivers for 2026 include Trastuzumab "Ansaiting," which is expected to exceed ¥100 million in sales in 2024 and continue significant growth in 2025. If not included in national procurement, the company will actively promote market layout for this product [1][2] - The long-acting follicle-stimulating hormone, exclusively represented by the company, has a potential national market size of over ¥4 billion. With only two competitors in the long-acting category, the product is expected to become a core offering, supported by national policies favoring fertility-related industries [2] Group 2: R&D Progress and Strategy - The company adopts an "independent innovation + external introduction" R&D model, collaborating with renowned scholars and experts to enhance its research capabilities. Ongoing clinical trials include "HuA21 injection," which has shown promising safety and efficacy in early studies and is moving towards Phase III trials [3][4] - The "AK2024 injection," targeting HER2, is currently in Phase I clinical trials, demonstrating superior synergistic effects compared to other treatments. The "HK010 injection," a dual antibody drug, has completed Phase II trials [3][4] Group 3: Strategic Collaborations and Market Positioning - The company is collaborating with Weisheng Pharmaceutical on the long-acting growth hormone "Lungpei," which has been approved for market entry. The product is positioned as a high-quality import, with plans for local production by 2028 [5] - The company’s subsidiary, Boshengji, is advancing its PA3-17 injection, which is in critical clinical trials and may become the first product in its field to market by the end of 2026 [6] Group 4: Innovations in Biotechnology - Boshengji is developing a dual-specific NK cell connector and a leading UCAR-Vδ1T product, which are expected to effectively target tumor heterogeneity [6] - Afana, another subsidiary, is focusing on mRNA vaccines for RSV and HPV, with its RSV mRNA vaccine being the first in China to complete Phase II clinical enrollment, showing excellent safety and efficacy [6]

Core Insights - The core viewpoint of the article is that Weisheng Pharmaceutical's innovative product, Weizhen Gao® (long-acting growth hormone), has received approval from the National Medical Products Administration, marking a significant milestone in the growth hormone market due to its unique technology and clinical advantages [1][2]. Product Core: Building a Differentiated Moat - Weizhen Gao® is the first long-acting growth hormone that maintains the natural structure of the active molecule, overcoming a significant industry technical barrier [2]. - The product utilizes a unique "TransCon" technology platform that allows for the temporary connection of the growth hormone with an inert carrier, enabling a controlled release of the active ingredient [2][3]. - Clinical studies have shown that Weizhen Gao® has superior efficacy compared to daily administration growth hormones, with significant improvements in annualized growth rate (AHV) and height standard deviation score (SDS) [3][4]. Market Strategy: Differentiated Commercial Pathway - The pricing strategy for Weizhen Gao® will reflect its unique attributes, with an expected annual treatment cost significantly higher than other long-acting growth hormones, justified by its clinical and technical advantages [7][8]. - Weisheng Pharmaceutical has adopted a "light asset, heavy cooperation" approach for market expansion, partnering with established companies for distribution and promotion [8][9]. - The company aims to establish a comprehensive "screening-diagnosis-management" process through collaborations with high-end private hospitals [9]. Team Building: High Standards for Execution - The company emphasizes a rigorous recruitment and training process for its commercial team, ensuring a high level of expertise and industry experience [10]. - A strict assessment mechanism is in place to maintain high standards of knowledge and performance among team members [10]. Long-term Outlook: From Single Product to Platform Value - The approval of Weizhen Gao® paves the way for future products under the TransCon technology platform, with significant sales potential anticipated for upcoming products targeting various endocrine disorders [14]. - The company aims to establish itself as a leading player in the endocrine and metabolic field, with a long-term goal of becoming a billion-dollar innovative pharmaceutical enterprise [14].